Pharmacokinetic characterization of a natural product–inspired novel MEK1 inhibitor E6201 in preclinical species

Purpose E6201 is a natural product–inspired novel inhibitor of mitogen-activated protein kinase/extracellular signal–regulated kinase kinase-1 (MEK1) and other kinases and is currently under development as an anticancer (parenteral administration) and antipsoriasis agent (topical application). In vitro and in vivo preclinical studies were performed to characterize the pharmacokinetics of E6201. Allometric scaling was applied to predict human pharmacokinetics of E6201.